Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Free Cash Flow (2019 - 2025)

Greenwich LifeSciences filings provide 6 years of Free Cash Flow readings, the most recent being -$2.7 million for Q3 2025.

  • Quarterly Free Cash Flow fell 3.38% to -$2.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$8.6 million through Sep 2025, down 13.51% year-over-year, with the annual reading at -$7.3 million for FY2024, 12.16% down from the prior year.
  • Free Cash Flow hit -$2.7 million in Q3 2025 for Greenwich LifeSciences, down from -$2.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$528270.0 in Q1 2021 and bottomed at -$2.7 million in Q3 2025.
  • Average Free Cash Flow over 5 years is -$1.6 million, with a median of -$1.8 million recorded in 2023.
  • The largest annual shift saw Free Cash Flow crashed 268.65% in 2022 before it increased 20.06% in 2023.
  • Greenwich LifeSciences' Free Cash Flow stood at -$2.3 million in 2021, then increased by 4.16% to -$2.2 million in 2022, then increased by 0.73% to -$2.2 million in 2023, then increased by 14.02% to -$1.9 million in 2024, then crashed by 44.22% to -$2.7 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Free Cash Flow are -$2.7 million (Q3 2025), -$2.2 million (Q2 2025), and -$1.8 million (Q1 2025).